Sugi Predict

Sugi Predict / Targets / GART

GART

Trifunctional purine biosynthetic protein adenosine-3 · P22102 · GART on Sugi Atlas →

9,294 patent compounds predicted against GART, 7,553 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL1603722 SCHEMBL1603722 1.00 18/20
SCHEMBL1603726 SCHEMBL1603726 1.00 18/20
SCHEMBL1605452 SCHEMBL1605452 0.77 18/20
SCHEMBL1605457 SCHEMBL1605457 0.77 18/20
SCHEMBL1604520 SCHEMBL1604520 0.71 18/20
SCHEMBL1604524 SCHEMBL1604524 0.71 18/20
SCHEMBL1604393 SCHEMBL1604393 0.61 18/20
SCHEMBL1604575 SCHEMBL1604575 0.58 18/20
SCHEMBL1604530 SCHEMBL1604530 0.56 18/20
SCHEMBL1603940 SCHEMBL1603940 1.00 17/20
SCHEMBL1603944 SCHEMBL1603944 1.00 17/20
SCHEMBL1604391 SCHEMBL1604391 1.00 17/20
SCHEMBL1604397 SCHEMBL1604397 1.00 17/20
SCHEMBL1604573 SCHEMBL1604573 1.00 17/20
SCHEMBL1604578 SCHEMBL1604578 1.00 17/20
SCHEMBL1604703 SCHEMBL1604703 1.00 17/20
SCHEMBL1604717 SCHEMBL1604717 1.00 17/20
SCHEMBL1604410 SCHEMBL1604410 0.78 17/20
SCHEMBL1604417 SCHEMBL1604417 0.78 17/20
SCHEMBL1604709 SCHEMBL1604709 0.78 17/20

Clinical trials — most relevant to GART by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
The Intervention of Multi-vitamin With Minerals to Hyperuricemia PHASE4UNKNOWN
Pharmacogenomic Evaluation of Antihypertensive Responses PHASE4COMPLETED
Acelarin First Line Randomised Pancreatic Study PHASE2/PHASE3SUSPENDED
Preventing Acute Kidney Injury (AKI) in Pediatric Patients PHASE3UNKNOWN
A Trial of CM-AT in Children With Autism With All Levels of FCT (The Blum Study) PHASE3COMPLETED
Effects of Vitamin B3 in Patients With Ataxia Telangiectasia PHASE2COMPLETED
NEO100 and High-Grade Meningioma PHASE2RECRUITING
Antifolate Effectiveness in Arthritis PHASE2COMPLETED
Folate Rechallenge PHASE2COMPLETED
Metronomic Chemotherapy With Tegafur/Uracil for Head and Neck Squamous Cell Carcinoma PHASE2UNKNOWN
Ataxia-telangiectasia: Treating Mitochondrial Dysfunction With a Novel Form of Anaplerosis PHASE2COMPLETED
Metabolic Cofactor Supplementation in Obese Patients With Non-Alcoholic Fatty Liver Disease PHASE2COMPLETED
Safety, Tolerability and Pharmacokinetics of Benfo-Oxythiamine (B-OT) in Healthy Volunteers PHASE1COMPLETED
Vatalanib and Pemetrexed Disodium in Treating Patients With Advanced Solid Tumors PHASE1COMPLETED
Nucleoside Therapy in Patients With Telomere Biology Disorders PHASE1RECRUITING
Ataxia-telangiectasia: Treating Mitochondrial Dysfunction With Nicotinamide Riboside nanUNKNOWN
Investigate eNAMPT in Multiple Myeloma Biology and Establish Its Role in Disease Progression nanCOMPLETED
Effect of Polymorphisms in the Adenosine a2a Receptor Gene and AMPD2 Gene on Adenosine-Induced Vasodilation and Reactive Hyperemia nanCOMPLETED
Role and Interactions of Adenosine, Receptors, Methionine Cycle Nutritional, Metabolic and Genetic Determinants in the Onset of Atrial Fibrillation in Normal Heart nanUNKNOWN
A Study of the Interaction Between Tumor Susceptibility Gene Glycine N-methyltransferase (GNMT) and Lung Cancer nanUNKNOWN
Plant-based Diets and Body Weight and Selected Metabolic Parameters Management in Obese Patients. nanCOMPLETED
Glycosylation in Patients With Galactosaemia nanCOMPLETED
TS Overexpression in SCLC: Mechanism and Therapeutic Targeting nanCOMPLETED
A Natural History Study Seeks to Understand the Clinical, Genomic, Pharmacological, Laboratory, and Dietary Determinates of Pyrimidine and Purine Metabolism Disorders nanRECRUITING
Role of Dairy Products in Weight Maintenance nanCOMPLETED
Evaluation of Adenosine Deaminase (ADA) Enzyme Deficiency in Patients With Lymphopenia and/or Elevated Immunoglobulin E nanUNKNOWN
Dietary Ketosis: Fatty Acids Activate AMPK Energy Circuits Modulating Global Methylation nanCOMPLETED
Sirtuin1 in COVID19 Patients nanUNKNOWN
Prevalence of Adenosine Deaminase (ADA) Enzyme Deficiency Disease in Adult Patients With Pulmonary Alveolar Proteinosis nanUNKNOWN
Thermogenic Silencer Regulatory Factors in Humans nanACTIVE_NOT_RECRUITING

Related proteins — ESM-2 sequence neighbours (a GART binder may also engage these)

ProteinNameSimilarity
Q64737 — 1.000 Q64737 →
P21872 — 1.000 P21872 →
Q59A32 — 1.000 Q59A32 →
Q99148 — 0.988 Q99148 →
P07244 — 0.987 P07244 →
P43848 — 0.987 P43848 →
A5UC39 — 0.986 A5UC39 →
A9IVF6 — 0.986 A9IVF6 →
A1JKZ7 — 0.985 A1JKZ7 →
A5UEU3 — 0.985 A5UEU3 →
Q4QKF3 — 0.985 Q4QKF3 →
B4TR76 — 0.985 B4TR76 →
P20772 — 0.985 P20772 →
B2HWV2 — 0.984 B2HWV2 →
A3M7X8 — 0.984 A3M7X8 →
P16340 — 0.984 P16340 →
Q9FDL5 — 0.984 Q9FDL5 →
Q54GJ2 — 0.984 Q54GJ2 →
Q4K8A5 — 0.984 Q4K8A5 →
G8EWC8 — 0.984 G8EWC8 →
B7GY98 — 0.984 B7GY98 →
Q8Z4R2 — 0.984 Q8Z4R2 →
A0LA23 — 0.983 A0LA23 →
P55195 — 0.983 P55195 →
Q01930 — 0.983 Q01930 →
Q6G5S5 — 0.983 Q6G5S5 →
Q6FZK1 — 0.983 Q6FZK1 →
B0URN5 — 0.983 B0URN5 →
Q2Y5R7 — 0.983 Q2Y5R7 →
B3E3K3 — 0.983 B3E3K3 →